Caspase Recruitment Domain Containing Protein 9 Suppresses Non-Small Cell Lung Cancer Proliferation and Invasion via Inhibiting MAPK/p38 Pathway
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Caspase recruitment domain containing protein 9 (CARD9) has been demonstrated to be a pro-tumor factor in various cancers. However, our previous study found a significant decrease of CARD9 in malignant pleural effusion compared with benign pleural effusion. So we investigated the role of CARD9 in non-small cell lung cancer (NSCLC) and its working mechanism. Materials and Methods Immunohistochemistry, western blot, and quantitative real-time polymerase chain reaction were used to detect the expression of CARD9 in specimens of NSCLC patients. The Cancer Genome Atlas (TCGA) database was also used to analyze the expression of CARD9 in NSCLC and its predicting value for prognosis. Immunofluorescence was used for CARD9 cellular location. Cell growth assay, clonal formation assay, wound healing assay, matrigel invasion assay, and flow cytometry were used to test cell proliferation, migration, invasion, apoptosis, and cycle progression of NSCLC cells with CARD9 knockdown or CARD9 overexpression. Co-immunoprecipitation was used to identify the interaction between CARD9 and B-cell lymphoma 10 (BCL10). SB203580 was used to inhibit p38 activation. Results CARD9 was decreased in NSCLC tissues compared with normal tissues; low CARD9 expression was associated with poor survival. CARD9 was expressed both in tumor cells and macrophages. Downregulation of CARD9 in NSCLC cells enhanced the abilities of proliferation, invasion, and migration via activated mitogen-activated protein kinases (MAPK)/p38 signaling, while overexpression of CARD9 presented antitumor effects. BCL10 was identified to interact with CARD9. Conclusion We demonstrate that CARD9 is an independent prognostic factor in NSCLC patients and inhibits proliferation, migration, and invasion by suppressing MAPK/p38 pathway in NSCLC cells.
Abstract
Purpose Caspase recruitment domain containing protein 9 (CARD9) has been demonstrated to be a pro-tumor factor in various cancers. However, our previous study found a significant decrease of CARD9 in malignant pleural effusion compared with benign pleural effusion. So we investigated the role of CARD9 in non-small cell lung cancer (NSCLC) and its working mechanism. Materials and Methods Immunohistochemistry, western blot, and quantitative real-time polymerase chain reaction were used to detect the expression of CARD9 in specimens of NSCLC patients. The Cancer Genome Atlas (TCGA) database was also used to analyze the expression of CARD9 in NSCLC and its predicting value for prognosis. Immunofluorescence was used for CARD9 cellular location. Cell growth assay, clonal formation assay, wound healing assay, matrigel invasion assay, and flow cytometry were used to test cell proliferation, migration, invasion, apoptosis, and cycle progression of NSCLC cells with CARD9 knockdown or CARD9 overexpression. Co-immunoprecipitation was used to identify the interaction between CARD9 and B-cell lymphoma 10 (BCL10). SB203580 was used to inhibit p38 activation. Results CARD9 was decreased in NSCLC tissues compared with normal tissues; low CARD9 expression was associated with poor survival. CARD9 was expressed both in tumor cells and macrophages. Downregulation of CARD9 in NSCLC cells enhanced the abilities of proliferation, invasion, and migration via activated mitogen-activated protein kinases (MAPK)/p38 signaling, while overexpression of CARD9 presented antitumor effects. BCL10 was identified to interact with CARD9. Conclusion We demonstrate that CARD9 is an independent prognostic factor in NSCLC patients and inhibits proliferation, migration, and invasion by suppressing MAPK/p38 pathway in NSCLC cells.
참고문헌 (27)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- "Cancer facts and figures 2019" (2019)[URL]
- Hsu YM, "The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens", Nat Immunol, 8, pp.198~205 (2007)
- Yang H, "pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2", Mol Cell, 28, pp.15~27 (2007)
- Cao Z, "Ubiquitin ligase TRIM62 regulates CARD9-mediated anti-fungal immunity and intestinal inflammation", Immunity, 43, pp.715~726 (2015)
- Nakamura S, "Overexpression of caspase recruitment domain(CARD)membrane-associated guanylate kinase 1(CARMA1)and CARD9 in primary gastric B-cell lymphoma", Cancer, 104, pp.1885~1893 (2005)
- Leo VI, "CARD9 promotes sex-biased colon tumors in the APCmin mouse model", Cancer Immunol Res, 3, pp.721~726 (2015)
- Tan W, "Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes", J Urol, 186, pp.2071~2077 (2011)
- Li H, "Proteomic study of benign and malignant pleural effusion", J Cancer Res Clin Oncol, 142, pp.1191~1200 (2016)
- Qu J, "CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production", Int J Cancer, 145, pp.2225~2237 (2019)
- Szklarczyk D, "The STRING database in 2017 : quality-controlled protein-protein association networks, made broadly accessible", Nucleic Acids Res, 45, pp.D362~D368 (2017)
- Jianhui Cai, "Tumor-Associated Macrophages Derived TGF-β-Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4", Snail Signaling Pathway, 2019, pp.51(1), 252~266[DOI]
- Hara H, "The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors", Nat Immunol, 8, pp.619~629 (2007)
- Saijo S, "Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans", Immunity, 32, pp.681~691 (2010)
- Robinson MJ, "Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection", J Exp Med, 206, pp.2037~2051 (2009)
- Yang M, "Tumor cell-activated CARD9 signaling contributes to metastasisassociated macrophage polarization", Cell Death Differ, 21, pp.1290~1302 (2014)
- Bergmann H, "Card9-dependent IL-1beta regulates IL-22 production from group 3 innate lymphoid cells and promotes colitis-associated cancer", Eur J Immunol, 47, pp.1342~1353 (2017)
- Liu M, "Dectin-1activation by a natural product beta-glucan converts immunosuppressive macrophages into an M1-like phenotype", J Immunol, 195, pp.5055~5065 (2015)
- Haas T, "Card9 controls Dectin-1-induced T-cell cytotoxicity and tumor growth in mice", Eur J Immunol, 47, pp.872~879 (2017)
- Qian BZ, "Macrophage diversity enhances tumor progression and metastasis", Cell, 141, pp.39~51 (2010)
- An J, "Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma", Cancer Res, 73, pp.1374~1385 (2013)
- LeibundGut-Landmann S, "Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17", Nat Immunol, 8, pp.630~638 (2007)
- Pereira M, "CARD9 negatively regulates NLRP3-induced IL-1beta production on Salmonella infection of macrophages", Nat Commun, 7, pp.12874~ (2016)
- Chen Z, "p38beta, A novel regulatory target of Pokemon in hepatic cells", Int J Mol Sci, 14, pp.13511~13524 (2013)
- Tomas-Loba A, "p38gamma is essential for cell cycle progression and liver tumorigenesis", Nature, 568, pp.557~560 (2019)
- Malik A, "SYK-CARD9 signaling axis promotes gut fungimediated inflammasome activation to restrict colitis and colon cancer", Immunity, 49, pp.515~530 (2018)
- Wang T, "The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells", Immunity, 49, pp.504~514 (2018)